AstraZeneca says detained China head has lawyer

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
DCC shares have jumped 17% in the FTSE 100 index after the Dublin-based conglomerate announced plans to focus on its energy ...
Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, ...